Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 9k
6 January 2021
E-000045/2021
Question for written answer  E-000045/2021
to the Commission
Rule 138
Marianne Vind (S&D)
 Answer in writing 
 Subject: Rheumatic and musculoskeletal diseases and research

Rheumatic and musculoskeletal diseases (RMDs) are chronic systemic diseases that commonly affect the joints, but which can also affect any organ in the body. There are more than 200 RMDs affecting Europeans of all ages. Around Europe it is estimated that over 100 million people live with RMDs, many of them still of working age. Early diagnosis and treatment of RMDs using relevant medical therapies and non-pharmaceutical interventions can improve quality of life while reducing the need for surgery. Therefore research, prevention and treatment of RMDs can help to facilitate greater workplace participation to the benefit of everyone. Besides being important for the RMD community, research into RMDs is of great benefit for other chronic conditions as well, as many research findings in this field directly benefit research on other major diseases.

Given that there are upcoming decisions related to European research funding, is the Commission planning to prioritise funding for research into the prevention and treatment of RMDs at European and national level in future plans, including the EU4Health programme?

Last updated: 21 January 2021Legal notice - Privacy policy